The Application and Effectiveness of CRISPR-Cas9 in Alzheimer's Disease and Parkinson's Disease
DOI:
https://doi.org/10.54097/pbjqff61Keywords:
CRISPR-Cas9 gene therapy; Alzheimer’s disease (AD); Parkinson’s disease (PD).Abstract
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are both types of neurodegenerative diseases (ND) that lead to severe failure in the nervous system. Usually, AD and PD are caused by genetic or environmental factors, and patients of AD or PD suffer from life inconveniences. AD and PD are both the major causes of irreversible dementia and can be classified into familiar and sporadic. A greater proportion of patients get sporadic AD and PD, and there hasn’t been an effective treatment for the diseases. Widely discussed in the 21st century, it is believed that CRISPR-Cas9 gene therapy may be a possible potential treatment for AD and PD because CRISPR-Cas9 is a such strong genetic modification tool. This passage summarizes papers from the past 5 years to demonstrate the mechanisms of AD and PD, and how these mechanisms related to the applications of CRISPR-Cas9 gene therapy. Also, the benefits and drawbacks of the therapy are discussed in detail.
Downloads
References
S. A. Tatulian, “Challenges and hopes for Alzheimer’s disease,” Drug Discovery Today, vol. 27, no. 4, pp. 1027–1043, Apr. 2022, doi: 10.1016/j.drudis.2022.01.016.
J. Jankovic and E. K. Tan, “Parkinson’s disease: etiopathogenesis and treatment,” J Neurol Neurosurg Psychiatry, vol. 91, no. 8, pp. 795–808, Aug. 2020, doi: 10.1136/jnnp-2019-322338.
H. Mollanoori and S. Teimourian, “Therapeutic applications of CRISPR/Cas9 system in gene therapy,” Biotechnol Lett, vol. 40, no. 6, pp. 907–914, Jun. 2018, doi: 10.1007/s10529-018-2555-y.
L. Lu, X. Yu, Y. Cai, M. Sun, and H. Yang, “Application of CRISPR/Cas9 in Alzheimer’s Disease,” Front. Neurosci. vol. 15, p. 803894, Dec. 2021, doi: 10.3389/fnins.2021.803894.
S.-W. Wang et al., “Current applications and future perspective of CRISPR/Cas9 gene editing in cancer,” Mol Cancer, vol. 21, no. 1, p. 57, Feb. 2022, doi: 10.1186/s12943-022-01518-8.
A. S. Hanafy, S. Schoch, and A. Lamprecht, “CRISPR/Cas9 Delivery Potentials in Alzheimer’s disease Management: A Mini Review,” Pharmaceutics, vol. 12, no. 9, p. 801, Aug. 2020, doi: 10.3390/pharmaceutics12090801.
E. Konstantinidis et al., “CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutation,” Molecular Therapy - Nucleic Acids, vol. 28, pp. 450–461, Jun. 2022, doi: 10.1016/j.omtn.2022.03.022.
N. C. Barman et al., “CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s disease—A Narrative Review,” Neurol Ther, vol. 9, no. 2, pp. 419–434, Dec. 2020, doi: 10.1007/s40120-020-00218-z.
Y. Duan et al., “Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer’s disease alleviates amyloid-related pathologies in mice,” Nat Biomed Eng, vol. 6, no. 2, pp. 168–180, Jul. 2021, doi: 10.1038/s41551-021-00759-0.
B. Yip, “Recent Advances in CRISPR/Cas9 Delivery Strategies,” Biomolecules, vol. 10, no. 6, p. 839, May 2020, doi: 10.3390/biom10060839.
L. M. De Plano, G. Calabrese, S. Conoci, S. P. P. Guglielmino, S. Oddo, and A. Caccamo, “Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders,” IJMS, vol. 23, no. 15, p. 8714, Aug. 2022, doi: 10.3390/ijms23158714.
T. B. Stoker and R. A. Barker, “Recent developments in the treatment of Parkinson’s Disease,” F1000Res, vol. 9, p. 862, Jul. 2020, doi: 10.12688/f1000research.25634.1.
P. Pinjala et al., “CRISPR/Cas9 assisted stem cell therapy in Parkinson’s disease,” Biomater Res, vol. 27, no. 1, p. 46, May 2023, doi: 10.1186/s40824-023-00381-y.
A. Klinkovskij, M. Shepelev, Y. Isaakyan, D. Aniskin, and I. Ulasov, “Advances of Genome Editing with CRISPR/Cas9 in Neurodegeneration: The Right Path towards Therapy,” 2023.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
